100481-09-2

Basic information

• Product Name: 2-Thiazolesulfonyl chloride
• Synonyms: 2-THIAZOLESULFONYL CHLORIDE;2-Thiazolesulfonylchloride(9CI);Thiazolesulfonyl chloride;thiazole-2-sulfonyl chloride;1,3-thiazole-2-sulfonyl chloride
• CAS NO: 100481-09-2
• Molecular Formula: C₃H₂ClNO₂S₂
• Molecular Weight: 183.64
• Product Categories: SULFONYLHALIDE;Thiazoles;Heterocycles;Sulfur & Selenium Compounds
• Mol File: 100481-09-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 328.523 °C at 760 mmHg
• Flash Point: 152.486 °C
• Appearance: Yellow oil
• Density: 1.688 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: -86?C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• PKA: -3.33±0.10(Predicted)
• CAS DataBase Reference: 2-Thiazolesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolesulfonyl chloride(100481-09-2)
• EPA Substance Registry System: 2-Thiazolesulfonyl chloride(100481-09-2)

Safety Data

• Hazardous Substances Data: 100481-09-2(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Oil

Uses

2-Thiazolesulfonyl chloride is used for preparation of substituted thiazolesulfonamides as antiglaucoma agents.

InChI:InChI=1/C3H2ClNO2S2/c4-9(6,7)3-5-1-2-8-3/h1-2H

Upstream product

• 288-47-1 1,3-thiazole 
• 109-72-8 n-butyllithium 
• 5685-05-2 2-mercaptothiazole 
• 3034-53-5 2-bromo-1,3-thiazole 

Downstream Products

• 1313217-19-4 tert-butyl [tert-butoxycarbonyl(6-{[4-(1,1-dimethylpentyl)benzyl](thiazol-2-ylsulfonyl)aminomethyl}pyridin-2-yl)amino]acetate 
• 1388234-62-5 2-(4-(4-((1,3-thiazol-2-yl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1257229-78-9 (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-(1,3-thiazol-2-ylsulfonyl)piperazine 
• 916913-93-4 methyl 3-methyl-4-[({6-[(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]benzoate 
• 916913-91-2 methyl 4-[({6-[(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]benzoate 
• 916913-92-3 methyl 4-({4,5-dimethyl-2-[(1,3-thiazol-2-ylsulfonyl)amino]phenoxy}methyl)-3-methylbenzoate 
• 916913-90-1 methyl 4-({4,5-dimethyl-2-[(1,3-thiazol-2-ylsulfonyl)amino]phenoxy}methyl)benzoate 
• 909896-97-5 methyl 4-{[2-[(1,3-thiazol-2-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 

Relevant articles and documents

Design and in vitro activities of N -alkyl- N -[(8- R -2,2-dimethyl-2 H -chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents

The hypoxia inducible factor (HIF) pathway is an attractive target for cancer, as it controls tumor adaptation to growth under hypoxia and mediates chemotherapy and radiation resistance. We previously discovered 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N- phenylbenzenesulfonamide as a novel, small-molecule HIF-1 pathway inhibitor in a high-throughput cell-based assay, but its in vivo delivery is hampered by poor aqueous solubility (0.009 μM in water; log P7.4 = 3.7). Here we describe the synthesis of 12 N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl) methyl]heteroarylsulfonamides, which were designed to possess optimal lipophilicities and aqueous solubilities by in silico calculations. Experimental log P7.4 values of 8 of the 12 new analogs ranged from 1.2-3.1. Aqueous solubilities of three analogs were measured, among which the most soluble N-[(8-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl]-N-(propan-2-yl) pyridine-2-sulfonamide had an aqueous solubility of 80 μM, e.g., a solubility improvement of ～9000-fold. The pharmacological optimization had limited impact on drug efficacy as the compounds retained IC50 values at or below 5 μM in our HIF-dependent reporter assay.

PLATELET ADP RECEPTOR INHIBITORS

no abstract published

11-BETA HSD1 1NHIBITORS

This invention features a chemical entity E, which is a compound of Formula I, or a salt (e.g., a pharmaceutically acceptable salt), or an N-oxide thereof (e.g., a compound of Formula I, or a pharmaceutically acceptable salt thereof). Formula I is provided below: formula (I) R1, R2, R3, R4, R5, R6, R7, R8, R9, and A can be as defined anywhere herein